Advertisement
Advertisement
U.S. markets close in 2 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Evofem Biosciences, Inc. (EVFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.41300.0000 (0.00%)
As of 03:59PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3830
Open0.3828
Bid0.0000 x 1100
Ask0.0000 x 3100
Day's Range0.3737 - 0.4600
52 Week Range0.2750 - 14.6100
Volume1,445,460
Avg. Volume36,554,109
Market Cap35.295M
Beta (5Y Monthly)-1.68
PE Ratio (TTM)N/A
EPS (TTM)-19.0060
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EVFM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evofem Biosciences, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
Advertisement
Advertisement